Health Care • Biotechnology: Laboratory Analytical Instruments
$1,674.81 ▼ -43.80
(-2.55%)
MKT CAP: $33.56B • VOL: 189.7K
52W L $1,023 52W H $1,729
MTD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.03B | $3.87B | $3.79B |
| YoY Revenue Growth % | +4.0% | +2.2% | — |
| Gross Profit | $2.39B | $2.33B | — |
| Gross Margin % | 59.4% | 60.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.03B | $1.02B | $930.8M |
| Operating Margin % | 25.5% | 26.3% | 24.6% |
| Net Income (GAAP) | $869.2M | $863.1M | $788.8M |
| EBITDA (Normalized) | $1.11B | $1.10B | $1.07B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $955.8M | $968.3M | $965.9M |
| Capital Expenditures (CapEx) | $107.1M | $103.9M | $170.5M |
| Free Cash Flow (FCF) | $848.6M | $864.4M | $795.4M |
| FCF Margin % | 21.1% | 22.3% | 21.0% |
| Return on Invested Capital (ROIC %) | 40.6% | 48.9% | 6.4% |
| Cash & Short-Term Equivalents | $66.9M | $59.4M | — |
| Total Debt (Short + Long Term) | $2.09B | $1.83B | $4.43B |
| Total Stockholders' Equity | -$23.6M | -$126.9M | $9.09B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MTD.